Photo - EnlitenAI
play_arrow
View
59437

EnlitenAI

USA, California
Market: Other, Artificial Intelligence, Biotech
Stage of the project: Prototype or product is ready

Date of last change: 20.02.2024
Go to the owner's profile
7
equalizer from 2000
help
Calculated and estimated occupancy of the project (more about ratings)
My rating
1
2
3
4
5
6
7
8
9
10
Average rating:
 

Idea

Built an AI platform for personalizing the treatment of seizures/Epilepsy using wearables for continuous monitoring of neurological indicators.

Our platform offers data monetization opportunities.

Current Status

1. Product readiness: Clinical Study at UCHealth (Colorado) completed and is a strong validation of our product.
2. Commercialization: Starts in Q3 2024
3. Strong market traction with
A. Neurology Centers: UCSF, UCHealth, Baylor, Univ of New Mexico
B. Devices - Apple, Emotiv, Neureka & Dreem3
D. EEG Annotation partner - TALOS
E. Endorsement by Epilepsy Foundation & invitation to be on their dtRRE panel
4. Reimbursement Strategy guidance created
5. Phased approach to FDA Regulatory Strategy (Class I in Q2'24 and Class II in Q4'24) - Software Assisted Medical Device

Problem or Opportunity

Neurologists are unable to build personalized treatment plans owing to the unpredictable nature of seizures and the lack of insights on patient specific responses to medications.  Drug titration is trial-and-error based and extremely long.  This leads to the skyrocketing cost burden for insurance carriers.  Today, wearable OEMs are able to detect seizures, but unable to synthesize real world evidence and optimize the treatment regimen is unaddressed today. They fall short.

EnlitenAI is addressing the unmet needs in personalizing the management of seizures, especially drug titration.

Solution (product or service)

Neuroliten is an AI based SaaS platform that has 3ponents -
1. Digital Seizure Diary - real world evidence
2. Data Ingestion Layer - captures ambulatory EEG data (using wearables) to detect brain signal abnormalities and Vitals (using smartwatch)
3. AI Engine - builds correlation and predictive models and insights needed to personalize treatment plans. Detects Tachyphylaxis, Guides Treatment aggressiveness and Drug titration to predict which medication has the highest rate of success for a patient given his/her co-medications, comorbidities, side effects & genetic predisposition.

Business model

Our commercialization strategy is based on a SaaS monetization model. Our Go-to-market strategy is B2B, wherein each neurology center is treated as a named account. The Neurologists advocate the use of our platform by prescribing Neuroliten to the patients.

The Neurology centers get reimbursed using Remote Therapeutic Monitoring codes, that already exist, by the Payers. Their incentive is to expand their practice, more frequent billing & see more patients for better health outcomes.

Neurology centers have an incentive to work with us they generate a new stream of revenue.

Incubation/Acceleration programs accomplishment

LifeX-Jumpstart Ventures
Innosphere Ventures
Aurelia Ventures
5,00
1
2
3
4
5
1 voice
Sign in/Sign up
arrow_back
EN
more_horiz
close
visibility451
star1
Add to favorites
Delete from favorites
share
close
thumb_up2
Like
Unlike
Idea
Current Status
Market
Problem or Opportunity
Solution (product or service)
Competitors
Advantages or differentiators
Finance
Invested in previous rounds, $
Business model
Money will be spent on
Offer for investor
Team or Management
Mentors & Advisors
Lead investor
Risks
Incubation/Acceleration programs accomplishment
Won the competition and other awards
Invention/Patent
Product Video
Presentation